Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin

Dae-Won Lee1, Sae-Won Han1,2, Jeong Mo Bae3, Hoon Jang4, Hyojun Han4, Hyoki Kim4, Duhee Bang5, Seung-Yong Jeong6, Kyu Joo Park6, Gyeong Hoon Kang3, and Tae-You Kim1,2,7

Abstract

Purpose: Recent sequencing studies revealed that a subset of colorectal cancer harbors a significantly higher number of somatic mutations. These hypermutated tumors show distinct clinicopathologic features. However, the prognostic impact of the hypermutated tumors is not clearly established.

Experimental Design: We analyzed tumor mutation burden (TMB) from targeted next-generation sequencing data of 40 major genes in 516 patients with colorectal cancer. TMB was defined as total number of non-synonymous mutations per tumor. Cutoff value for TMB-high was chosen by which best discriminated relapse-free survival (RFS) using the Contal and O’Quigley method.

Results: In the TCGA data, mutation count of the selected 40 genes reflected the whole exome mutation burden (Pearson correlation = 0.873, P < 0.001). In our patient cohort, 8 or more mutations in the 40 genes was defined as TMB-high, which best discriminated RFS. A total of 55 patients (10.7%) had TMB-high. TMB-high tumors were more frequently found in a proximal location (63.6%) and had a higher proportion of N0 disease (30.9%) and MSI-H (49.1%) compared with TMB-low. Most importantly, TMB-high was associated with better 5-year RFS compared with TMB-low (96.3% vs. 79.8%, P = 0.005). Although there was significant overlap between TMB-high and MSI-H, MSI-H status was not significantly associated with RFS. Multivariate analysis revealed TMB-high as an independent positive prognostic factor for RFS [adjusted HR, 0.16 (95% confidence interval, 0.04–0.66), P = 0.011].

Conclusions: TMB-high is associated with better prognosis in patients with colorectal cancer treated with curative surgery followed by adjuvant fluoropyrimidine and oxaliplatin chemotherapy.

Introduction

Colorectal cancer is a heterogeneous disease resulting from complex genetic and epigenetic alterations (1). The Cancer Genome Atlas (TCGA) performed comprehensive molecular analysis of colorectal cancer using exome sequence, DNA copy number, promoter methylation, and messenger RNA and microRNA expression (1). TCGA revealed that 16% of colorectal cancer is categorized as hypermutated tumors (mutation rates of >12 per 106 base pair). Hypermutated tumors were more frequently found in proximal tumor location and 77% had microsatellite instability-high (MSI-H) feature. Microsatellite stable (MSS) hypermutated tumor usually had somatic mutations in mismatch-repair genes or POLE aberrations. They also identified that hypermutated tumor and non-hypermutated tumor have different genetic characteristics. APC, TP53, KRAS, PIK3CA, FBXW7, SMAD4, TCF7L2, and NRAS were the 8 most frequently mutated genes in non-hypermutated tumors. In the hypermutated tumors, ACVR2A, APC, TGFBR2, MSH3, MSH6, SLC9A9, and TCF7L2 were frequently mutated. Although hypermutated tumors had higher mutation rates compared with non-hypermutated tumors, TP53 (20% vs. 60%, P < 0.0001) and APC (51% vs. 81%, P = 0.0023; both Fisher exact test) were less frequently mutated in hypermutated tumor. Although TCGA group speculated that hypermutated tumor may have favorable prognostic role, the prognostic role of hypermutated tumors could not be evaluated due to heterogeneous population and limited number of patients. The prognostic association of tumor mutation burden (TMB) in stage II or III colorectal cancer was recently reported in patients enrolled in the QUASAR 2 clinical trial which compared the efficacy of adjuvant capecitabine plus bevacizumab with adjuvant capecitabine alone (2). In the study, TMB-high was associated with longer relapse-free survival (RFS) in patients with colorectal cancer treated with adjuvant capecitabine plus bevacizumab whereas MSI-H was not associated with prognosis (2).
Translational Relevance

A subset of colorectal cancer is characterized as having a significantly higher number of somatic mutations. These hypermutated tumors are frequently found in proximal tumor location and have a high incidence of microsatellite instability-high feature. Recently, tumor mutation burden (TMB) has been highlighted by the fact that it may be a positive predictive factor for immune checkpoint inhibitors. However, data on the prognostic role of TMB are limited, especially in the adjuvant setting. In this study, we show that TMB-high is associated with better treatment outcome in stage III or high-risk stage II colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. In addition to validation of this finding, the mechanism underlying the better survival in TMB-high patients needs to be elucidated in future studies.

More than 80% of colorectal cancer arise in a stepwise transformation of normal colorectal epithelium to an adenoma and ultimately to an invasive carcinoma, traditionally known as the adenoma-carcinoma sequence (3). In addition, approximately 15% of colorectal cancer displays MSI-high tumor which results from deficient mismatch repair (MMR) system (4). MSI-H colorectal cancer may have favorable outcome in stage II/III patients, whereas the prognostic role in stage IV disease is less concrete (5, 6). More importantly, it has been identified that MSI-H tumors have high response to PD-1 blockade regardless of tumor subtype (7–9). In a study performed in 86 MMR-deficient patients including 40 (47%) colorectal cancer, the objective response rate of anti-PD-1 antibody pembrolizumab was 53% (8). There was no difference in objective response rate between colorectal cancer and noncolorectal cancer (52% vs. 54%; ref. 8). Evidences show that TMB is a potential biomarker to predict efficacy of immunotherapy (10, 11). Tumors with high TMB may present more neoantigens, which can be recognized by a host immune system (10). It is suspected that the high mutation burden of MSI-H tumors may have affected its response to immunotherapy (9). However, it is not known whether TMB or MSI-H is more important in responses to immunotherapy or determining patient prognosis. Moreover, it is not clear whether the favorable prognostic role of MSI-H is due to TMB or vice versa.

The purpose of this study was to evaluate the prognostic role of TMB in patients with stage III or high-risk stage II colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy, which is the current standard of care in patients with stage III colorectal cancer after surgical resection (12). TMB was calculated using a targeted sequencing data of 40 genes included in 5 critical pathways of colorectal cancer. The impact of MSI-H on survival was also analyzed.

Materials and Methods

Patients and treatment

In this study, TMB was analyzed in a previously reported colorectal cancer cohort which identified the prognostic role of 5 critical pathways (13). The study population is a retrospective consecutive series identified by searching electronic medical record database of Seoul National University Hospital (SNUH). We searched for patients who had received fluoropyrimidine and oxaliplatin after curative surgery and patients were included if they met the inclusion criteria (13). In brief, 516 patients with stage III or high-risk stage II colorectal who received at least 6 cycle of adjuvant FOLFOX or 4 cycle of adjuvant XELOX chemotherapy at Seoul National University Hospital (SNUH, Seoul, South Korea) were included. High-risk stage II was defined if the patient had any of the following: T4 lesion, obstruction or perforation, lymphovascular invasion, perineural invasion, poorly differentiated histology. All patients received curative surgery prior to adjuvant chemotherapy and upper rectal cancer were included if the patient did not receive pre- or postoperative radiation. None of the patients received anti-EGFR or anti-VEGF treatment for adjuvant chemotherapy. Patient received adjuvant chemotherapy as either FOLFOX-4 (229 patients), modified FOLFOX-6 (166 patients), or XELOX (121 patients). Adjuvant FOLFOX and XELOX chemotherapy was planned for a total of 12 and 8 cycles, respectively. The study protocol was reviewed and approved by the institutional review board of SNUH [H-1210-016-430]. This study was carried out in accordance with the recommendations of the Declaration of Helsinki for biomedical research involving human subjects.

TMB using targeted sequencing of 40 genes associated with 5 critical pathways

Every exon of the 40 genes associated with the 5 critical pathways of colorectal cancer was sequenced (13). Fourteen genes were selected from WNT pathway (ARID1A, AMER1, APC, AXIN2, CTNNB1, DKK1, DKK2, DKK3, DKK4, FRXV7, FZD10, LR59, SOX9, TCF7L2), 2 genes from P53 pathway (ATM, TP53), 8 genes from RTK-RAS pathway (BRAF, EGFR, ERBB2, ERBB3, ERBB4, HRAS, KRAS, NRAS), 7 genes from TGFβ pathway (ACVR1B, ACVR2A, SMAD2, SMAD3, SMAD4, TGFB1R, TGFB2R), and 9 genes from PI3K pathway (IGF1R, IGF2, IRS2, MTOR, PIK3CRA, PIK3CA, PIK3R1, PTEN, SRC). As a result, a total of 109,161 base pair was sequenced. Detailed methods for targeted sequencing can be found in our previous article (13). In brief, genomic DNA (>200 ng) samples were sheared and prepared according to routine library preparation. The captured library was amplified and sequenced using Hiseq 2500 (Illumina). Sequencing data were filtered with a mean quality Q20 (Phred score) per read, and these filtered data were aligned to GRCh37 using bwa 0.7.5a. The aligned reads were processed with Picard Mark Duplicates and GATK base recalibration. After a series of processes, the aligned bases were pileup with SAM tools. Variant call and somatic analysis processes were performed by Varscan and were annotated with ANNOVAR. TMB were calculated using the total number of nonsynonymous somatic mutations. We used Contal and O’Quigley statistical method to define cutoff value for TMB-high tumors using RFS. Contal and O’Quigley method categorize a continuous variable into a binary variable with a cutoff point which have the maximum HR based on a log rank test (14).

Microsatellite analysis

The microsatellite status of each tumor was determined by evaluating 5 microsatellite markers (D2S123, D5S346, D17S250, BAT25, and BAT26; ref. 13). Either the forward or reverse primer for each marker was labeled with fluorescence and PCR products were electrophoresed and analyzed. We classified the MSI status as follows: MSI-high (MSI-H; instability at 2 or more microsatellite

Published OnlineFirst July 8, 2019; DOI: 10.1158/1078-0432.CCR-19-1105

Downloaded from clincancerres.aacrjournals.org on November 20, 2021. © 2019 American Association for Cancer Research.
Tumor Mutation Burden in Colorectal Cancer

Analysis of TMB using TCGA database

TCGA data was downloaded from the Genomic Data Commons Data Portal (GDC portal, https://portal.gdc.cancer.gov/). The TCGA database included 433 COAD (colon adenocarcinoma) case and 158 READ (rectal adenocarcinoma) case. In total, 591 colorectal cancer patients from the TCGA database were analyzed. Somatic mutations were identified using the MuTect algorithm as analyzed in the TCGA article (1). The correlation analysis between mutation burden of selected 40 genes and whole exome mutation burden was identified using Pearson correlation coefficient.

Statistical analysis

The primary objective of this study was to investigate the effect of TMB on RFS. Secondary objectives were to evaluate the effect of TMB on overall survival (OS), and to compare the clinical characteristics and prognostic role of TMB and MSI-H. The clinical database was last updated in February 2017. RFS was calculated using the Kaplan–Meier method, and comparisons of RFS were performed using the log-rank test. OS was defined as the time from date of operation to death from any cause. Categorical variables were compared by chi-square test or Fisher exact test, and continuous variables were compared using the independent-samples T test. RFS and OS were considered statistically significant if the patient had 8 or more mutations (>8). Patients with 7 or less mutation (<7) were regarded as TMB-low. Among 516 patients, 55 (10.7%) patients had TMB-high tumor (Fig. 1C). TMB-high tumor tended to occur in proximal location (63.6% vs. 30.6% in TMB-low, P = 0.004), and were more frequently altered in TMB-high tumors compared to TMB-low (P = 0.001). patients with TMB-high tumor had MAC histology. Baseline characteristics including age, sex, and T stage were similar between TMB-high and TMB-low.

Mutational characteristics according to TMB

The detailed mutation count of patients with MSI-H is shown in Table 2. In accordance with the result from the TCGA data, TP53 was less frequently mutated in TMB-high tumors compared to TMB-low tumors (38.2% vs. 66.8% in TMB-low tumor, P < 0.001; ref. 1). Although most genes were more frequently mutated in TMB-high tumors, the mutation rate of APC gene were similar between TMB-high and TMB-low tumors (78.2% vs. 71.6%, P = 0.30). Likewise, pathways were more frequently altered in TMB-high tumor, except for TP53 pathway (as a result of TP53 mutation rate).

RFS. OS was defined as the time from date of operation to death from any cause. The correlation analysis between mutation burden of selected 40 genes and whole exome mutation burden was identified using Pearson correlation coefficient.

Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Total (N = 516)</th>
<th>TMB-Low (N = 461)</th>
<th>TMB-High (N = 55)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65 years</td>
<td>346 (67.1%)</td>
<td>307 (66.6%)</td>
<td>39 (70.9%)</td>
<td>0.52</td>
</tr>
<tr>
<td>≥65 years</td>
<td>170 (32.9%)</td>
<td>154 (33.5%)</td>
<td>16 (29.1%)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>304 (58.9%)</td>
<td>269 (58.4%)</td>
<td>35 (63.6%)</td>
<td>0.45</td>
</tr>
<tr>
<td>Female</td>
<td>212 (41.1%)</td>
<td>192 (41.6%)</td>
<td>20 (36.4%)</td>
<td></td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proximal</td>
<td>176 (34.1%)</td>
<td>141 (30.6%)</td>
<td>35 (63.6%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Distal</td>
<td>340 (65.9%)</td>
<td>320 (69.4%)</td>
<td>20 (36.4%)</td>
<td></td>
</tr>
<tr>
<td>T stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>3 (0.6%)</td>
<td>2 (0.4%)</td>
<td>1 (1.8%)</td>
<td>0.20</td>
</tr>
<tr>
<td>T2</td>
<td>24 (4.7%)</td>
<td>24 (5.2%)</td>
<td>0 (0.0%)</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>412 (79.8%)</td>
<td>367 (79.6%)</td>
<td>45 (81.8%)</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>77 (14.9%)</td>
<td>68 (14.8%)</td>
<td>9 (16.4%)</td>
<td></td>
</tr>
<tr>
<td>N stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>86 (16.7%)</td>
<td>69 (15.0%)</td>
<td>17 (30.9%)</td>
<td>0.004</td>
</tr>
<tr>
<td>N1</td>
<td>288 (55.8%)</td>
<td>258 (56.0%)</td>
<td>30 (54.5%)</td>
<td></td>
</tr>
<tr>
<td>N2</td>
<td>142 (27.5%)</td>
<td>134 (29.1%)</td>
<td>8 (14.5%)</td>
<td>0.13</td>
</tr>
<tr>
<td>N3</td>
<td>430 (83.3%)</td>
<td>392 (85.0%)</td>
<td>38 (69.1%)</td>
<td></td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-MAC</td>
<td>492 (95.3%)</td>
<td>438 (95.0%)</td>
<td>54 (98.2%)</td>
<td>0.29</td>
</tr>
<tr>
<td>MAC</td>
<td>24 (4.7%)</td>
<td>23 (5.0%)</td>
<td>1 (1.8%)</td>
<td></td>
</tr>
<tr>
<td>Microsatellite status (N = 512)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSS/MSI-L</td>
<td>475 (92.4%)</td>
<td>446 (97.6%)</td>
<td>29 (51.9%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MSI-H</td>
<td>39 (7.6%)</td>
<td>11 (2.4%)</td>
<td>28 (50.0%)</td>
<td></td>
</tr>
</tbody>
</table>

www.aacrjournals.org  Published OnlineFirst July 8, 2019; DOI: 10.1158/1078-0432.CCR-19-1105
Prognostic role of TMB-high tumor and MSI-H

After a median follow up duration of 62.4 months, the 5-year RFS of the entire cohort was 81.5% [95% confidence interval (CI), 78.0%–85.0%] and the 5-year OS was 90.2% (95% CI, 87.5%–92.9%). Five-year RFS, which is the primary objective, was significantly better in TMB-high tumor compared with TMB-low tumor (5-year RFS 96.3% vs. 79.8%, respectively; \( P = 0.005 \); Fig. 2A). As MSI-H is historically known as a positive prognostic factor and is closely related to TMB-high, we performed additional analysis to see whether MSI-H have a prognostic role. In contrast to TMB, MSI status was not associated RFS (5-year RFS of 89.7% in MSI-H vs. 81.0% in MSS/MSI-L, \( P = 0.23 \); Fig. 2C). Tumor location also did not impact RFS (\( P = 0.92 \)).

Multivariate analysis using the Cox proportional hazard model revealed TMB-high tumor [adj HR for RFS 0.16 (95% CI, 0.04–0.66), \( P = 0.011 \)] as an independent positive prognostic factor for RFS (Table 3).

In an exploratory subgroup analysis, TMB-high tumor had a positive prognostic role in both MSI-H and MSS/MSI-L patients (Supplementary Fig. S1). TMB-L/MSI-H patients tended to have the worst prognosis. However, this result should be interpreted with caution given the small number of patients in the majority of the subgroups. Although TMB-high tumor had high incidence of stage II disease, TMB-high was a positive prognostic factor in a subgroup of patients with stage III disease (5-year RFS 97.3% vs. 79.8%, respectively; \( P = 0.014 \)).

In the analysis of OS, which is the secondary objective, TMB-high tumor had a tendency of favorable survival compared with TMB-low tumor (5-year OS 96.2% vs. 89.6%, respectively; \( P = 0.060 \); Fig. 2B). However, TMB-high tumor was not an independent prognostic factor for OS in the multivariate analysis. MSI-H was not associated with OS (Fig. 2D).

**Discussion**

This study was conducted to investigate whether TMB have prognostic role in patients with stage III or high risk II colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. TMB was calculated using the targeted sequencing data of 40 genes which represent 5 critical pathways of colorectal cancer. Using the TCGA database, we confirmed that the mutation number of selected 40 genes were able to represent whole exome mutation burden. We were able to show that TMB-high is associated with favorable RFS in patients with stage III or high risk II colorectal cancer using a small set of genes important in colorectal cancer.

Development of colorectal cancer arise in a stepwise order through chromosomal instability known as the adenoma–carcinoma sequence (3). However, approximately 15% of colorectal cancer is characterized by MSI-H (4). MSI-H colorectal cancer tends to have favorable prognosis in early-stage tumors.
and have distinct clinical and pathologic features. Previous studies suggest that there is an ethnic difference in the incidence of MSI-H, CIMP, and BRAF mutation, which are lower in Asian compared with Western (15). Recently, the clinical relevance of MSI-H has been highlighted by the fact that it is a strong predictive biomarker for immune checkpoint inhibitors (7, 8). Because of defect in MMR system, MSI-H tumors have high TMB. As a result, MSI-H tumors create higher tumor-specific neoantigens and have more tumor infiltrating lymphocytes compared with MSS tumors (16–18). It is speculated that the high mutation burden and its resulting tumor-specific neoantigens of MSI-H tumors may have affected its response to immunotherapy (9).

Although MSI-H tumors usually have high TMB, not every colorectal cancer with high TMB show MSI-H feature (1). In this study, TMB-high tumor was shown in 55 (10.7%) among 516 patients. MSI-H was found in 39 (7.6%) patients and half of TMB-high tumors were MSI-H. In the TCGA database, 16% of colorectal cancers were found to be hypermutated and 14% had MSI-H feature. Among hypermutated tumor, 77% had MSI-H feature (1). The proportion of TMB-high tumor and the proportion of MSI-H

Table 3. Multivariate analysis of RFS

<table>
<thead>
<tr>
<th>Variable</th>
<th>Status</th>
<th>Adjusted HR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor stage (T)</td>
<td>T1-T4*</td>
<td>2.91 (1.90–4.43)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lymph node stage (N)</td>
<td>N0-N2*</td>
<td>1.89 (1.38–2.59)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TMB</td>
<td>TMB-Low</td>
<td>1</td>
<td>0.011</td>
</tr>
<tr>
<td></td>
<td>TMB-High</td>
<td>0.16 (0.04–0.66)</td>
<td>0.013</td>
</tr>
<tr>
<td>RTK-RAS pathway</td>
<td>Wild type</td>
<td>1</td>
<td>0.013</td>
</tr>
<tr>
<td></td>
<td>Mutation</td>
<td>1.73 (1.12–2.66)</td>
<td></td>
</tr>
</tbody>
</table>

*Continuous variable.
in high TMB tumor was lower in our cohort compared with TCGA data. The lower incidence of MSI-H in Asian patients with colorectal cancer may have affected such finding (15). Recent evidence revealed that proofreading domain mutation of POLE could result in hypermutated tumors (19). As we do not have explanation for the high mutation burden in MSS patients, it would be important to analyze genes including mismatch repair genes and POLE in the future studies to identify underlying cause of the high mutation burden. Although many studies showed favorable prognosis of MSI-H colorectal cancer, there are conflicting results especially in metastatic disease (5, 6). In our study, MSI-H was not associated with RFS and OS. By contrast, TMB-high was associated with lower recurrence and had tendency of favorability OS. Interesting finding was that MAC histology, which is frequently found in MSI-H colorectal cancer and is a potent poor prognostic factor (20, 21), was rarely shown in TMB-high tumor. In addition, TMB was variable among MSI-H tumors, and TMB-high patients had better RFS although the finding is based on a small number of patients in this study. Previous studies have shown that number of frameshift mutations and neoantigen load are associated with tumor infiltrating lymphocytes (22, 23). Immune cell infiltration is associated with better prognosis in colorectal cancer (24, 25). Taken together, different immune response among MSI-H according to TMB status may have influenced RFS. TMB and MAC histology may have partially affected contradictory role of MSI-H in previous studies. TMB maybe a more reliable prognostic factor compared with MSI-H. The favorable prognostic role of high TMB in stage II and III colorectal cancer was previously reported by Domingo and colleagues (2). However, none of the patients in the discovery cohort received standard fluoropyrimidine plus oxaliplatin chemotherapy, and only 47 patients (under 10%) received fluoropyrimidine plus oxaliplatin chemotherapy in the validation cohort (2). The novelty of our study is that all patients in our cohort were treated with curative surgery followed by adjuvant fluoropyrimidine plus oxaliplatin chemotherapy, which is the current standard treatment for patients with stage III colorectal cancer (12). Recently, the positive prognostic role of high TMB was also noticed in MSS metastatic colorectal cancer (26). From the database of CALGB/SWOG 80405 study, the authors revealed that high TMB tumor had longer OS compared with low TMB tumor (HR = 0.73, P = 0.02) in patients with MSS metastatic colorectal cancer. This study result once again confirms that TMB is a positive prognostic factor in patients with colorectal cancer. Future study investigating the predictive role of TMB on immune check point inhibitor would be helpful in patients with colorectal cancer.

There are several limitations in this study. As TMB was measured with targeted sequencing of 40 genes, only 109,161 base pair was sequenced in each patient. In addition, TMB-high tumor was defined using the cutoff point which have the best HR for RFS. However, our gene panel is specific to colorectal cancer and all 40 genes were included in the 5 critical pathways of colorectal cancer. As a result, 511 patients (99.0%) had at least 1 nonsynonymous mutation and the median number of nonsynonymous mutation was 4. Moreover, the mutation burdens of selected 40 genes were associated whole exome mutation burden in the TCGA database. Our study results suggest that even gene panel with limited number of genes can be used as a useful tool to identify TMB, when selected properly to a tumor subtype. Another major limitation of this study is that we could not validate the association of TMB-high with prognosis in the TCGA data set because of the limited number of stage III patients (N = 155) with survival data. The finding needs to be validated with an independent cohort in the future studies.

In conclusion, high TMB is associated with favorable outcome in patients with stage III or high risk II colorectal cancer treated with fluoropyrimidine and oxaliplatin chemotherapy. However, MSI-H was not associated with survival.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Availability of Data and Materials
The datasets used and/or analyzed during this study are available from the corresponding author on reasonable request.

Ethics Approval and Consent to Participate
The study protocol was reviewed and approved by the institutional review board of SNUH (H-1210-016-430). This study was carried out in accordance with the recommendations of the Declaration of Helsinki for biomedical research involving human subjects. In accordance with South Korea regulation, retrospective studies without any additional therapy or monitoring procedure, do not need formal written consent from patients. Because the study was retrospectively designed without any investigational intervention, the study-specific informed consent was not obtained from each patient (https://cris.snuh.org, http://bri.snuh.org).

Authors' Contributions
Conception and design: D.-W. Lee, S.-W. Han, S.-Y. Jeong, T.-Y. Kim
Development of methodology: S.-W. Han
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D.-W. Lee, S.-W. Han, J.M. Bae, S.-Y. Jeong, K.J. Park, G.H. Kang
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): D.-W. Lee, S.-W. Han, H. Jung, H. Han, H. Kim, D. Bang
Writing, review, and/or revision of the manuscript: D.-W. Lee, S.-W. Han, S.-Y. Jeong, K.J. Park
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.-W. Han, J.M. Bae, H. Han, G.H. Kang
Study supervision: D.-W. Lee, S.-W. Han, H. Kim, T.-Y. Kim
Other (performing an experiment): H. Han

Acknowledgments
This research was supported by the Seoul National University Hospital (SNUH) Research Fund (03-2014-0440) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant Nos.: H144C1277 and H13C2163).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 1, 2019; revised May 21, 2019; accepted July 1, 2019; published first July 8, 2019.

References
2. Domingo E, Camps C, Kaisaki PJ, Parsons MJ, Mouradov D, Pentony MM, et al. Mutation burden and other molecular markers of prognosis in...
Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin

Dae-Won Lee, Sae-Won Han, Jeong Mo Bae, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-19-1105

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2019/07/04/1078-0432.CCR-19-1105.DC1

Cited articles
This article cites 26 articles, 9 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/25/20/6141.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/25/20/6141.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.